# Compare the Efficacy and Safety of Beta-Glucan as Add-On to Statin in Subjects With Hyperlipidemia.

> **NCT03857256** · PHASE2 · COMPLETED · sponsor: **Montreal Heart Institute** · enrollment: 263 (actual)

## Conditions studied

- Hyperlipidemias

## Interventions

- **DRUG:** CP105F
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03857256
- **Lead sponsor:** Montreal Heart Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-31
- **Primary completion:** 2021-08-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2024-01-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03857256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03857256, "Compare the Efficacy and Safety of Beta-Glucan as Add-On to Statin in Subjects With Hyperlipidemia.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03857256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*